---
- :source_cl_identifier: ''
  :source_cl_notation: LBTEST
  :source_cli_identifier: C125949
  :instructions: Urea Nitrogen can be measured in substances other than Blood, Serum,
    or Plasma. This concept will replace C61019.
  :references:
  - C61019
- :source_cl_identifier: ''
  :source_cl_notation: LBTEST
  :source_cli_identifier: C125950
  :instructions: Urea Nitrogen can be measured in substances other than Blood, Serum,
    or Plasma. This concept will replace C74753.
  :references:
  - C74753
- :source_cl_identifier: ''
  :source_cl_notation: LBTEST
  :source_cli_identifier: C61019
  :instructions: Urea Nitrogen can be measured in substances other than Blood, Serum,
    or Plasma. Therefore please use the generic code for Urea Nitrogen (C125949),
    which has been published with the 2016-03-25 publication.
  :references:
  - C125949
- :source_cl_identifier: ''
  :source_cl_notation: LBTEST
  :source_cli_identifier: C74753
  :instructions: Urea Nitrogen can be measured in substances other than Blood, Serum,
    or Plasma. Therefore please use the generic code for Urea Nitrogen/Creatinine
    (C125950), which has been published with the 2016-03-25 publication.
  :references:
  - C125950
- :source_cl_identifier: ''
  :source_cl_notation: LBTESTCD
  :source_cli_identifier: C125949
  :instructions: Urea Nitrogen can be measured in substances other than Blood, Serum,
    or Plasma. This concept will replace C61019.
  :references:
  - C61019
- :source_cl_identifier: ''
  :source_cl_notation: LBTESTCD
  :source_cli_identifier: C125950
  :instructions: Urea Nitrogen can be measured in substances other than Blood, Serum,
    or Plasma. This concept will replace C74753.
  :references:
  - C74753
- :source_cl_identifier: ''
  :source_cl_notation: LBTESTCD
  :source_cli_identifier: C61019
  :instructions: Urea Nitrogen can be measured in substances other than Blood, Serum,
    or Plasma. Therefore please use the generic code for Urea Nitrogen (C125949),
    which has been published with the 2016-03-25 publication.
  :references:
  - C125949
- :source_cl_identifier: ''
  :source_cl_notation: LBTESTCD
  :source_cli_identifier: C74753
  :instructions: Urea Nitrogen can be measured in substances other than Blood, Serum,
    or Plasma. Therefore please use the generic code for Urea Nitrogen/Creatinine
    (C125950), which has been published with the 2016-03-25 publication.
  :references:
  - C125950
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C121932
  :instructions: The nomenclature has been updated and now the original mapping is
    obsolete. This concept will replace C27477.
  :references:
  - C27477
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C126087
  :instructions: This concept will replace C72074 and C3773, which have been removed
    with the 2016-03-25 publication.
  :references:
  - C72074
  - C3773
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C126088
  :instructions: This concept will replace C64118, which has been removed with the
    2016-03-25 publication.
  :references:
  - C64118
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C27477
  :instructions: The nomenclature has been updated and now the original mapping is
    obsolete. Please use C121923 in place of C27477.
  :references:
  - C121923
  - C27477
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C2858
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C2915
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C2932
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3017
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3055
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3059
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3070
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3087
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3146
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3188
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3230
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3234
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3262
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3286
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3288
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3308
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3326
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3340
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3403
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3411
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3486
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C35765
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3738
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3764
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3773
  :instructions: Replace with NEUROENDOCRINE CELL TUMOR, MALIGNANT (C126087). Please
    use C126087 in place of 3773.
  :references:
  - C126087
  - C126087
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3788
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C3794
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C4313
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C48306
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C4858
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C60781
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C64118
  :instructions: Replace with RENAL MESENCHYMAL TUMOR, MALIGNANT (C126088). Please
    use C126088 in place of C64118.
  :references:
  - C126088
  - C126088
  - C64118
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C6930
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C6963
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C72074
  :instructions: Replace with NEUROENDOCRINE CELL TUMOR, MALIGNANT (C126087). Please
    use C126087 in place of C72074.
  :references:
  - C126087
  - C126087
  - C72074
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C7367
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C82973
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C8402
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C9295
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: NEOPLASM
  :source_cli_identifier: C98794
  :instructions: The FDA requires non-clinical sponsors to identify Benign or Malignant
    so this concept would never be used.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: PKUNIT
  :source_cli_identifier: C85780
  :instructions: Creatinine belongs in test/parm name. Please use pg/mg (C67396) in
    its place.
  :references:
  - C67396
- :source_cl_identifier: ''
  :source_cl_notation: TOXGRV4
  :source_cli_identifier: C48275
  :instructions: As per the SDTM implementation guide, the name and version of the
    AE grading scale goes into the define XML. These values are governed by external
    codelists.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: TOXGRV4
  :source_cli_identifier: C75533
  :instructions: As per the SDTM implementation guide, the name and version of the
    AE grading scale goes into the define XML. These values are governed by external
    codelists.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: TOXGRV4
  :source_cli_identifier: C84263
  :instructions: As per the SDTM implementation guide, the name and version of the
    AE grading scale goes into the define XML. These values are governed by external
    codelists.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: TOXGRV4
  :source_cli_identifier: C84264
  :instructions: As per the SDTM implementation guide, the name and version of the
    AE grading scale goes into the define XML. These values are governed by external
    codelists.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: TOXGRV4
  :source_cli_identifier: C84265
  :instructions: As per the SDTM implementation guide, the name and version of the
    AE grading scale goes into the define XML. These values are governed by external
    codelists.
  :references: []
- :source_cl_identifier: ''
  :source_cl_notation: TOXGRV4
  :source_cli_identifier: C84266
  :instructions: As per the SDTM implementation guide, the name and version of the
    AE grading scale goes into the define XML. These values are governed by external
    codelists.
  :references: []
- :source_cl_identifier: C87162
  :source_cl_notation: TOXGRV4
  :source_cli_identifier: ''
  :instructions: As per the SDTM implementation guide, the name and version of the
    AE grading scale goes into the define XML. These values are governed by external
    codelists.
  :references: []
